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Abstract
A characteristic feature of celiac disease is the presence of circulating autoantibodies targeted against transglutaminase 2
(TG2), reputed to have a function in angiogenesis. In this study we investigated whether TG2-specific autoantibodies
derived from celiac patients inhibit angiogenesis in both ex vivo and in vivo models and sought to clarify the mechanism
behind this phenomenon. We used the ex vivo murine aorta-ring and the in vivo mouse matrigel-plug assays to address
aforementioned issues. We found angiogenesis to be impaired as a result of celiac disease antibody supplementation in
both systems. Our results also showed the dynamics of endothelial cells was affected in the presence of celiac antibodies. In
the in vivo angiogenesis assays, the vessels formed were able to transport blood despite impairment of functionality after
treatment with celiac autoantibodies, as revealed by positron emission tomography. We conclude that celiac
autoantibodies inhibit angiogenesis ex vivo and in vivo and impair vascular functionality. Our data suggest that the anti-
angiogenic mechanism of the celiac disease-specific autoantibodies involves extracellular TG2 and inhibited endothelial cell
mobility.
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Introduction
Angiogenesis, the formation of blood vessels, has emerged as an
essential phenomenon involved in various disorders. Also intestine-
related diseases, such as inflammatory bowel disease, ascites and
peritoneal adhesions, are characterized or contributed by dysreg-
ulated blood vessel growth or formation [1]. In inflammatory
bowel disease, for instance, it has been demonstrated that
increased vascularization is present in the inflamed colonic
mucosa of the patients and the expression of several angiogenic
factors is markedly increased [2,3]. Similarly, untreated celiac
disease patients have been reported to evince abnormalities in
their small-intestinal mucosal vasculature [4,5]. In addition to
these vascular aberrations, untreated celiac patients have disease-
specific circulating autoantibodies targeted against transglutamin-
ase 2 (TG2) in their sera and as deposits in their small-intestinal
mucosa. In the mucosa autoantibodies are bound to TG2 below
the epithelium on the basement membrane and interestingly also
around blood vessels [6,7].
The target of the celiac autoantibodies, TG2, is a ubiquitously
expressed enzyme involved in a wide range of cellular processes
including angiogenesis. TG2, expressed highly by endothelial cells,
contributes to angiogenesis by cross-linking a variety of extracel-
lular matrix (ECM) proteins through the formation of Ca2+-
dependent covalent linkages [8,9]. Celiac disease-specific TG2-
targeted autoantibodies have been proposed to disturb endothelial
cell biology in vitro [10,11], but information about their capability
to interfere with vessel formation and function in more complex ex
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vivo and in vivo systems is not available. This study was designed
specifically to address the question what kind of effects the celiac
disease-specific autoantibodies have on vascular formation and
functionality ex vivo and in vivo and to discover the mechanism
behind.
Materials and Methods
Ethics statement
The protocol for mouse studies was approved by the Finnish
and Hungarian authorities, the Turku Central Animal Laboratory
(University of Turku, Finland) and the Debrecen University
animal facility (Debrecen, Hungary). The study protocol for using
human serum samples was approved by the Ethics Committee of
Tampere University Hospital, Tampere, Finland, and written
informed consent was received from all subjects.
Animals
For ex vivo and in vivo studies, 4–6-week-old female Balb/c mice
(Harlan Laboratories Inc. Horst, the Netherlands) or C57BL/6
wild type or TG2 knockout mice [12], were housed at 22uC in a
12-hour light/dark cycle with water and food freely available. The
animals were cared for and used in accordance with the
regulations in Finland, Hungary and the European Union (86/
609/EC).
Purification of serum IgA and production of monoclonal
antibodies
Serum samples from three biopsy-proven celiac disease patients
on a gluten-containing diet and positive for both anti-TG2
(.100 U/ml; Celikey, Phadia GmbH, Freiburg, Germany) and
endomysial antibodies (1:.2,000) were employed in the study. As
controls we used serum samples from three non-celiac controls,
which all were negative for the above-mentioned antibodies. Total
IgA fractions from serum samples were purified as previously
described [10], using cyanogen bromide-activated Sepharose 4B
(Pharmacia Upjohn, Uppsala, Sweden) coupled with 7 mg/ml
rabbit anti-human IgA antibodies (Sigma Aldrich, St Louis, MO,
USA). Thereafter, the IgA samples were lyophilized and
resolubilized in Hank’s balanced salt solution to a final concen-
tration of 100 mg/ml. Purified antibodies were used in the
experiments at a concentration of 1 mg/ml.
The following IgG-class recombinant monoclonal autoantibod-
ies prepared from celiac patients were used: celiac patients’ anti-
TG2 specific monoclonal antibodies targeting the major celiac
epitope; clone 4.1 (CD Mab) and irrelevant control antibodies
(clones 5.1 and 6.2, non-CD Mab) targeted against Escherichia
coli proteins M5 and M6 [13,14]. Recombinant technology was
essentially applied in Chinese hamster ovary cells to produce the
monoclonal antibodies as previously described [15], which were
used in the experiments at a concentration of 1 mg/ml.
Ex vivo aorta ring and in vivo matrigel plug angiogenesis
assays
Mouse aortas were cut into 0.5 mm-thick rings and embedded
in matrigel (BD Biosciences, Bedford, MA, USA) containing CD
Mabs or their respective controls, non-CD Mabs. The aorta rings
were cultured in EGM-2 plus endothelial cell growth factors
provided in the EGM-2 Bulletkit (Clonetics, San Diego, CA, USA)
for ten days. Thereafter, images of endothelial sprouts and
interconnected capillary tubes were randomly taken using a Zeiss
inverted microscope and Axiovision 3.0 program (Carl Zeiss
Vision GmbH, Mu¨nchen-Hallbergmoos, Germany). The pictures
were analyzed using ImageJ software (http://rsb.info.nih.gov/ij)
[16].
In vivo mouse angiogenesis assays were performed using matrigel
(BD Biosciences) containing 10 mg/kg of erythropoietin (EPO;
Sigma Aldrich, St. Louis, MO, USA), which was injected
subcutaneously into the backs of mice. This system is based on
the EPO-induced self-production of vessels by cells migrating into
the matrigel plugs from the host [17–20]. CD Mabs or their
respective controls were mixed with matrigel and injected to
recipient mice. After eight days, some of the mice were examined
by positron emission tomography (PET). Finally, the matrigel
plugs were removed from all animals, snap-frozen and stored at
280uC for further analysis.
In vitro angiogenesis assays
In vitro assays were performed using human umbilical vein
endothelial cells (HUVECs) purchased from Lonza (Cambrex Bio
Science, Walkersville, MD, USA). HUVECS were cultured at
37uC and 5% CO2 in endothelial growth medium-1 (EGM-I;
Clonetics). EGM-I consists of endothelial cell basal medium
(EBM-I; Clonetics) and endothelial cell growth factors provided in
the EGM-I Bulletkit (Clonetics).
HUVECs (2.56105cells/well) were mixed with matrigel (BD
Biosciences; diluted 1:3 in EGM-1) and celiac patient-derived IgA
(CD IgA) or CD Mab or their respective controls (non-CD IgA
and non-CD Mab). In a subset of experiments we used an active
site-directed irreversible extracellular TG2 inhibitor R281 at a
concentration of 200 mM [21]. In this case, the inhibitor was
administered one hour prior to addition of antibodies. After
48 hours images of different fields were randomly taken using a
Zeiss inverted microscope and Axiovision 3.0 program (Carl Zeiss
Vision GmbH, Mu¨nchen-Hallbergmoos, Germany). Length,
branch, area and number of endothelial tubules were measured
using ImageJ analysis software.
In addition, HUVECs embedded in matrigel as described above
were cultured for ten days in Cell-IQ (Chip-man Technologies
LTD, Tampere, Finland). Briefly, the system consists of a cell
incubator containing an integrated system designed to take and
analyze images. During the assays images were taken every five
minutes. The Cell IQ software was used for further enumeration
of apoptotic and immobile cells and video editing. For the analysis
of cell movements cells were tracked using MTrack tool in ImageJ
software.
In vivo vascular functionality assay
Balb/c mice, injected subcutaneously with matrigel plugs as
described above, received an intravenous injection of Hoechst
33342 (Hoechst; Invitrogen, Carlsbad, CA, USA) five minutes
before euthanasia. Thereafter, the plugs were snap-frozen after
excision and stored at 280uC until further analysis.
Positron emission tomography
In this experiment one mouse received three matrigel implants,
each treated with PBS (basal group), non-CD Mab or CD Mab
and injected subcutaneously into separate limbs. Mice were
anesthetised with isoflurane and intravenously injected with 2-
[18F]-fluoro-2-deoxy-D-glucose ([18F]FDG). PET imaging for
20 minutes was performed using an Inveon Multimodality scanner
(Siemens Medical Solutions, Knoxville, TN) at 60 minutes post
injection and reconstructed with the ordered-subsets expectation
maximization 2D algorithm (OSEM2D). After PET imaging the
animals were euthanised and the matrigel plugs excised, weighed
and measured for radioactivity using a gamma counter (Triathler
30, Hidex, Turku, Finland), which was cross-calibrated with a dose
Celiac Autoantibodies Inhibit Angiogenesis In Vivo
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calibrator (VDC-202, Veenstra Instruments, Joure, the Nether-
lands). Quantitative analysis was performed by drawing regions of
interest in the matrigel plug areas (Vinci software, version 2.54;
Max Planck Institute for Neurological Research, Cologne,
Germany). The average radioactivity concentration (kBq/ml) in
the regions of interest was used to verify in vivo results.
Electron microscopy
Aortas collected from the mice and treated as described above
were prepared for electron-microscopy analysis. Briefly, the
specimens were cut to 1 mm thickness, fixed in 5% glutaraldehyde
(Electron Microscopy Sciences, Fort Washington, PA, USA) in
0.16 M s-collidin buffer (pH 7.4) and post-fixed with potassium
ferrocyanide-osmiun tetroxide as previously described [22].
Samples were embedded in epoxy resin (Glycidether 100, Merck,
Darmstadt, Germany) and cut into thin sections (70 nm) [22].
Sections were stained with 5% uranyl acetate and 5% lead citrate
in an Ultrostainer (Leica, Wien, Austria) and examined under a
JEM-100SX transmission electron microscope (JEOL, Tokyo,
Japan).
Immunofluorescence studies
Frozen sections from mouse matrigel plugs were fixed in 4%
paraformaldehyde and processed to 5–7-mm-thick sections. The
presence of vessels in the matrigel implants was studied by
immunofluorescent labeling with an anti-von Willebrand factor
(vWF) antibody (1:200, Dako, Glostrup, Denmark) and counter-
stained with a secondary antibody labeled with Alexa-488 (1:1000,
Molecular Probes, Eugene, OR, USA) at room temperature.
Nuclei were stained with Vectashield mounting medium contain-
ing 49,6-diamidino-2-phenylindole (DAPI; Vector Laboratories,
Inc., Burlingame, CA, USA). Images were taken with an Olympus
BX60 microscope (Olympus Europa GmbH, Hamburg, Ger-
many) and CellD imaging software (Olympus Europa GmbH,
Hamburg, Germany). Quantitative data were obtained by
counting the number and diameter of vWF-positive blood vessels
as well as the total number of cells per matrigel area in digitalized
images using ImageJ software.
Figure 1. Angiogenesis is impaired ex vivo and in vivo after
treatment with celiac disease patient monoclonal autoanti-
bodies. (A) Representative figures taken from mouse aorta rings
cultured inside matrigel for ten days in the presence of monoclonal
celiac disease-specific transglutaminase 2 antibody (CD Mab) or its
respective control (non-CD Mab). Scale bars represent 100 mm. Bars
represent different angiogenic parameters. (n = 4 aortas per group). (B)
Representative pictures of mouse matrigel implants treated with CD
Mab or non-CD Mab. After eight days the implants were removed and
stained for blood vessels with von Willebrand factor (vWF)-antibody
(green) and blue color indicates nuclei (DAPI). Scale bar represents
200 mm. Bars show vascular parameters measured from matrigel
implants. (n = 8 animals per group). Bars in both charts, A and B,
represent the average value as percentage + SEM. All data was
normalized to the basal group (dotted line). * represents P#0.001
statistical difference.
doi:10.1371/journal.pone.0065887.g001
Figure 2. Cellular behavior is altered in the presence of celiac
autoantibodies. (A) Transmission electron micrographs of mouse
aorta ring experiments in the presence of monoclonal celiac patient-
derived transglutaminase 2-targeted antibody (CD Mab) or its
respective control (non-CD Mab). Arrows indicate the extracellular
matrix (ECM)-free area in the leading edges of the cells treated with
non-CD Mab and the white dotted line shows an area of densely
organized ECM around a cell treated with CD Mab. Scale bar represents
6 mm. (B) Representative images taken from mouse matrigel implants
treated with CD Mab or non-CD Mab. Nuclei are shown as blue (DAPI)
from the border and center of the implants. Scale bar represents
300 mm.
doi:10.1371/journal.pone.0065887.g002
Celiac Autoantibodies Inhibit Angiogenesis In Vivo
PLOS ONE | www.plosone.org 3 June 2013 | Volume 8 | Issue 6 | e65887
Demonstration of TG2 in the matrigel
First, 100 ml of matrigel (BD Biosciences) was jellified and mixed
with 100 ml of Laemmli-buffer. After ten minutes the samples were
sonicated and centrifuged for ten minutes at 12 000 rpm at 4uC.
Subsequently, the samples were concentrated with acetone. The
protein concentrations were measured by the Bradford method
and 20 mg of total protein was loaded on 10% polyacryl amide gels
(1.5 M Tris–HCl, pH 8.8; sodium dodecyl sulfate, 12%; acrylam-
ide/bis-acrylamide, 30%; APS, 10%; and TEMED), followed by
transfer to a Hybond-P membrane (Amersham Biosciences, Little
Chalfont, Bucks, UK). After blocking in 5% milk, the membrane
was incubated with mouse monoclonal antibody against TG2,
CUB7402 (1:200, Santa Cruz Biotechnology Inc, Santa Cruz, CA,
USA), followed by a secondary rabbit antibody conjugated with
horseradish peroxidase. Detection was performed with the ECL
PlusWestern Blotting Detection System (ECL, GE Healthcare
Biosciences, Pittsburgh, PA, USA).
Statistical analysis
Statistical comparisons were made using statistical analysis
software (PASW Statistics 18, SPSS Inc., Chicago, IL, USA). The
data were first tested for homogeneity. When the data fulfilled this
criterion and there were three or more groups involved in an
experiment, one-way ANOVA analysis was used. A two-way
ANOVA within subjects was used to compare the effect of TG2
inhibitor with respect to each treated group. In both cases a
Student Newman Keuls (SNK) test was performed as post hoc
analysis. Non-homogeneous data were compared with Kruskal-
Wallis test and further tested by Mann-Whitney U test. The data
are presented as mean 6 standard error of mean (SEM), a p-
value#0.05 being considered significant.
Results
Celiac disease antibodies impair angiogenesis ex vivo and
in vivo
To investigate the effects of celiac disease antibodies on
angiogenesis occurring in an assay, which recapitulates all the
key steps in the process including matrix degradation, migration,
proliferation and reorganization, we performed ex vivo aorta ring
experiments. Using this system, we observed that the number of
the tubules, the microvascular area and the maximum microvessel
outgrowth were significantly reduced in the presence of CD Mab
as compared to non-CD Mab (P#0.001; Figure 1A). As definitive
tests for angiogenesis require in vivo experiments, we next
performed mouse matrigel experiments. In this assay our results
were parallel to those obtained from aorta ring experiments as
both the number and diameter of the vessels inside the matrigel
Figure 3. Endothelial cell dynamics in the presence of celiac
patient-derived total IgA (CD IgA) or monoclonal antibodies
(CD Mab), or their relevant controls (non-CD IgA or non-CD
Mab). (A) The number of long tubules (.36 mm) was counted from
videos taken from human umbilical vein endothelial cell (HUVEC)
cultures during a 48 hour time course in the presence of CD IgA or CD
Mab, or their relevant controls non-CD IgA or non-CD Mab. (B) HUVECs
were tracked for 48 hours and cellular mobility during that time course
is indicated in representative pictures. Each color represents an
individual cell. (C) The percentage of immobile cells (left panel) and
the cell mobility in micrometers (right panel) were determined in the
cell cultures treated with CD IgA or CD Mab or their relevant controls.
Bars represent the average value as percentage + SEM. Basal group is
indicated as a dotted line. * represents P#0.001 statistical difference.
doi:10.1371/journal.pone.0065887.g003
Figure 4. Functionality of vessels in mice in the presence of
celiac patient-derived monoclonal autoantibodies (CD Mab) or
their relevant controls (non-CDMab). (A) Representative images of
mouse matrigel implants were treated with CD Mab or non-CD Mab.
Hoechst 33342 (Hoechst) was injected intravenously into a tail vein five
minutes prior to euthanasia. The removed implants were stained for
blood vessels with anti-von Willebrand factor (vWF)-antibody (green).
Blue color indicates Hoechst-stained nuclei (DAPI) and scale bar
represents 200 mm. (B) Vascular functionality parameters were deter-
mined from matrigel implants (left panel) and the ratio of Hoechst- and
vWF-positive area was calculated (right panel). (n = 4 animals per
group). Bars represent the average value as percentage + SEM. All data
was normalized to the basal group (dotted line). * represents P#0.05
statistical difference.
doi:10.1371/journal.pone.0065887.g004
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were significantly decreased in the presence of CD Mab (P#0.001;
Figure 1B).
To gain further insight into the effects of celiac antibodies, we
took transmission electron microscope images from ex vivo mouse
aorta ring assays, and observed that in control cultures there were
pseudopodia in the protruding leading edges of cells and
pericellular areas free of ECM (Figure 2A). In contrast, in the
presence of celiac patient TG2-targeted autoantibodies cells
outgrowing from mouse aortas were round and did not exhibit
cellular processes characteristic for the leading edge during
migration. Furthermore, the mouse matrigel implants were used
to study the localization of cells migrating from the mice to the
plug. We found that in the basal group and in the group treated
with non-CD Mab, cells had migrated from the animal even to the
center of the matrigel and were evenly distributed inside the
matrigel implant. In contrast, in the matrigels treated with CD
Mab, cells were mainly located in the border of the matrigel and
only few were found in the central area (Figure 2B).
Dynamics of endothelial cell behavior is altered in the
presence of celiac disease antibodies
The data obtained from aorta ring and mouse matrigel
experiments suggested that the anti-angiogenic effects exerted by
celiac antibodies could be contributed by defective migration. To
study this further we took videos of HUVECs growing inside
matrigel. In cultures supplemented with control antibodies, the
formation of tubule-like structures was evident after 20 hours of
culture. However, in the presence of celiac antibodies (both total
CD IgA and CD Mab) the formation of tubule-like structures,
especially long ones (.36 mm), was inhibited when compared to
controls during the 48 hour time course (Figure 3A, Video S1).
Concurrently, the number of branches and tubules after 48 hours
of culture were significantly reduced in the cultures treated with
IgA and CD Mab compared to controls (Figure S1).
Tracking of cells grown inside matrigel revealed that in the
presence of celiac antibodies the number of immobile cells was
increased. The cells that did move regardless of the presence of
celiac antibodies, moved half of the distance of those cultured in
the presence of their relevant control antibodies (P#0.001).
However, cellular mobility showed extensive variability among
experimental groups (Figure 3B, C). To exclude the possibility that
the anti-angiogenic effects of celiac disease antibodies are due to
increased apoptosis, we quantified the number of apoptotic cells
and found that their number was not increased in the presence of
celiac antibodies (Figure S2).
Celiac disease TG2-specific antibodies affect in vivo
vascular functionality
We next studied capillary perfusion in in vivo matrigel implants
using an intravenous tail vein injection of Hoechst [23]. In all
treatment groups the vessels inside the matrigel were functional,
since in each case the injected dye was located around blood
vessels (Figure 4A). The percentage of the Hoechst-positive area
was similar in all groups, whereas the area occupied by vWF-
staining was significantly reduced in the group treated with CD
Mab (P#0.05). The ratio between the Hoechst- and vWF-positive
areas was 2.6 times higher in the group treated with CD Mab than
in the relevant control (Figure 4B).
The functionality of the vessels formed inside in vivo matrigel
implants was also studied by PET (Video S2). We found that
[18F]FDG uptake was decreased in the matrigel treated with CD
Mab in comparison with non-CD Mab (P#0.05) but not with
basal group. However, the matrigel implants treated with CDMab
contained significantly fewer vessels than controls (P#0.05). The
ratio of [18F]FDG uptake and vessel area was increased more than
two fold in CD Mab-treated matrigel implants than in the controls
(Figure 5A, B).
The contribution of extracellular TG2 in the anti-
angiogenic response
As extra- and intracellular TG2 have been demonstrated to be
involved in distinct endothelial cell processes [24], we next studied
whether the anti-angiogenic response by celiac disease antibodies
is mediated by cellular or extracellular TG2. To this end, we first
tested the role of extracellular TG2 by pretreating HUVEC
cultures with the cell-impermeable TG2 inhibitor R281 and found
that the inhibitor was able to restore the tubule length of CD IgA-
or CD Mab-treated cells to control level (P#0.001; Figure 6A).
To confirm the contribution of extracellular TG2, we
performed experiments using TG2 knockout mice. By definition,
TG2 knockout mice do not express cellular TG2 [12], whereas
Figure 6B clearly demonstrates that matrigel itself, used in the
following experiments as extracellular growth environment,
contains significant amounts of extracellular TG2. Ex vivo aorta
ring assay with TG2 knockout mouse tissue showed that in the
presence of CD Mab the microvessel and maximum outgrowth
areas were decreased slightly but not significantly (Figure 6C). On
the other hand, the in vivo matrigel plug assays performed in the
knockout animals demonstrated that the vascular area in the
implants was significantly reduced after CD Mab treatment
(P#0.01; Figure 6D). It is of note that the overall angiogenic
Figure 5. Vessel functionality studied by positron emission
tomography (PET). (A) 2-[18F]-fluoro-2-deoxy-D-glucose ([18F]FDG)
PET scans of mice implanted with matrigel (basal) or supplemented
with celiac disease-specific monoclonal autoantibodies (CD Mab) or
control antibodies (non-CD Mab). Each mouse received three matrigel
implants (basal, CD Mab or non-CD Mab), each injected subcutaneously
into separate limb as highlighted by circles in the scan. The magnitude
of [18F]FDG uptake is defined in different colors. (n = 3) (B) The uptake of
[18F]FDG in the implants was analyzed from the PET images and the
area occupied by vessels was determined by von Willebrand factor
(vWF)-antibody staining (left panel). The ratio of [18F]FDG uptake and
vascular area was calculated (right panel). Bars represent average value
as percentage + SEM. All data was normalized to the basal group
(dotted line). * represents P#0.05 statistical difference.
doi:10.1371/journal.pone.0065887.g005
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response in TG2 knockout mice was reduced when compared to
wild type animals of the same mouse strain (Figure 6C–D).
Discussion
Previous in vitro findings suggest that celiac disease-specific TG2-
targeted autoantibodies disturb angiogenesis in two-dimensional
cell cultures [10,14,25]. The data presented in this article clearly
demonstrate that celiac disease autoantibodies are anti-angiogenic
also in more complex ex vivo systems using mouse aorta rings
grown in three-dimensional conditions. Moreover, our data show
for the first time that angiogenesis is hindered by celiac antibodies
also in vivo in mice. In addition, the present results demonstrate
that celiac disease-specific TG2 autoantibodies affect the func-
tionality of vessels in vivo, which would confirm the previously
suggested effects of celiac autoantibodies on endothelial perme-
ability [11].
The data presented in Figure 3 strongly suggest that the anti-
angiogenic effects of celiac antibodies are attributable to affected
endothelial cell mobility, but also their reduced capacity to form
sprouts and to establish cell-cell contacts. During the angiogenic
process, the breakdown of the matrix in the leading edge of a
migrating cell is a prerequisite for proper movement [26,27]. In
cultures supplemented with CD Mab, such areas of proteolytic
degradation were not present and instead the cells were
surrounded by electron-dense areas of ECM. These observations
would indicate that in the presence of celiac autoantibodies ECM
degradation/remodeling is disturbed, which could contribute to
defective mobility discussed above. Interestingly, it has been shown
that the administration of catalytically active TG2 causes an
accumulation of ECM and defective angiogenesis in vitro [9].
Together this and our current finding, that cell-impermeable
TG2-inhibitor R281 prevented the anti-angiogenic effects of celiac
antibodies, would suggest that extracellular TG2 activity is
involved in impaired angiogenic response in the presence of celiac
antibodies. Another plausible explanation how R281 could rescue
impaired angiogenesis is by preventing the binding of the celiac
antibodies to TG2 but according to previous data [11] this did not
seem to be the case.
Results obtained from experiments performed with TG2
knockout mice showed that in the in vivo matrigel plug de novo
angiogenesis assay, where only the extracellular TG2 was present
supplied by the matrigel itself, the angiogenic response was
significantly decreased after CD Mab treatment. This observation
underlines the importance of extracellular TG2 in the anti-
angiogenic effect exerted by celiac disease antibodies. In the aorta
ring experiments there was only a trend towards reduced
microvessel and maximum outgrowth areas in the presence of
CD Mab, the change was not however statistically significant.
These somewhat discrepant results could be partly explained by
the fact that in the TG2 knockout mice the overall angiogenic
response in matrigel was greatly reduced compared to wild type
animals while in the aorta ring experiment the reduction was not
that extensive. This is probably due to differences in experimental
settings, because in the matrigel plug assay the cells first have to
migrate to plug to form vessels, whereas in the aorta ring assay
cells can initiate the angiogenic process immediately. It is possible
that also other factors, such as the proportion endogenous ECM
secreted by the aortic tissue or individual migrating cells, might
contribute to discrepancy.
Figure 6. The contribution of extracellular transglutaminase 2 (TG2) in the anti-angiogenic response exerted by celiac antibodies.
(A) Endothelial tubule length in three-dimensional human umbilical vein endothelial cell (HUVEC) cultures in the presence of celiac patient-derived
total IgA (CD IgA) or monoclonal antibodies (CD Mab), or their relevant controls (non-CD IgA or non-CD Mab) and with/without TG2-inhibitor R281.
All data was normalized to the basal group (dotted line). Bars represent the average value as percentage + SEM. * represents P#0.001 statistical
difference (n = 9). (B) Western blot using anti-TG2 antibody CUB7402 showing the presence of TG2 in the matrigel. (C) Mouse aorta rings derived from
TG2 knockout mice (TG22/2) were cultured inside TG2-containing matrigel for ten days without supplementation (basal) or in the presence of CD
Mab or non-CD Mab. After the culture period the vascular area and the maximum outgrowth were measured (n = 5 aortas per group). (D) In vivo
angiogenesis assays were performed in TG22/2 mice. Matrigel containing endogenous TG2 was supplemented with CD Mab or non-CD Mab and
injected to mice. After eight days the implants were removed and the vascular area determined by anti-von Willebrand factor (vWF)-antibody
staining. (n = 8 animals per group). Bars in charts C and D represent the average value as percentage + SEM. All data was normalized to the wild type
mouse basal group (dotted line). * represents P#0.01 statistical difference.
doi:10.1371/journal.pone.0065887.g006
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The data derived from in vivo Hoechst injections and PET scans
suggest that the vessels formed in matrigel in the presence of celiac
autoantibodies are functional, as they transported the marker
molecules injected into the circulation. However, the vascular area
was smaller in the groups treated with CD Mab in both
experiments. This would suggest that the functionality of the
vessels was impaired either due to increased permeability or
immaturity of the vessels. Because the number of vessels and their
diameter were diminished in the presence of celiac autoantibodies,
it is reasonable to assume that the latter alternative, the immaturity
of the vessels, could explain our findings of impaired functionality.
A similar state of immaturity, lacking a sufficient smooth muscle
supportive layer, has previously been demonstrated in the small-
intestinal mucosa of celiac disease patients [4].
Our present findings show that the celiac disease-specific
autoantibodies interfere with angiogenesis in vivo. Thus, TG2-
targeted autoantibody deposits around blood vessels in celiac
patient small bowel mucosa [7] could be anti-angiogenic and lead
to altered small bowel mucosal vasculature. This abnormal
vascular network would no longer be able to provide mechanical
support to the villi and thereby contribute to the development of
villus atrophy. Interestingly, the association between morpholog-
ical changes in intestinal mucosa and angiogenesis is supported by
a recent paper, which describes that olmesartan, one of several
angiotensin II receptor antagonists used for management of
hypertension, was found to be associated with unexplained chronic
diarrhea and small intestinal villus atrophy in patients taking the
drug [28]. The same drug has been published to reduce
angiogenesis in mice [28,29].
The changes in the small-bowel mucosal vasculature in celiac
disease might not only affect the mucosal architecture; they may
also contribute to the pathogenesis in other ways. The celiac
autoantibodies acting in concert with other factors including
inflammatory mediators [30] could also potentiate the small-bowel
mucosal inflammatory response by increasing the permeability of
the vessels.
We conclude that celiac autoantibodies inhibit angiogenesis in
three-dimensional ex vivo experiments, but also importantly in vivo
in mice. The data presented in this article suggest that the anti-
angiogenic mechanism of the disease-specific autoantibodies
involves extracellular TG2 activity contributing to disruption of
ECM remodeling. These could lead to inhibited endothelial cell
mobility and finally to impaired angiogenesis. Defective angio-
genesis could be coupled with compromised vascular function
induced by celiac patient TG2-targeted autoantibodies and
explain the findings of abnormal small-bowel vasculature in
untreated celiac disease.
Supporting Information
Figure S1 Three-dimensional endothelial cell tubule
formation assay. Several angiogenic parameters quantified
from human umbilical vein endothelial cells cultured inside
matrigel for 48 h without any supplementation (basal) or in the
presence of celiac patient-derived total IgA (CD IgA) or
monoclonal antibodies (CD Mab), or their relevant controls
(non-CD IgA or non-CD Mab; n= 9). Bars represent the average
value as percentage + SEM. All data was normalized to the basal
group (dotted line). * represents P#0.001 statistical difference.
(TIF)
Figure S2 The percentage of apoptotic cells in the
presence of celiac antibodies Apoptotic human umbilical
vein endothelial cells inside matrigel cultures without any
supplementation (basal) or in the presence of celiac patient-
derived total IgA (CD IgA) or its respective control (non-CD IgA),
or monoclonal celiac or control antibodies (CD Mab or non-CD
Mab, respectively) were enumerated after 1, 15, 30 and 48 hours
of culture with Cell-IQ from the videos. Results are given as
percentages of total cell number.
(TIF)
Video S1 Tubule dynamics of endothelial cells supple-
mented with celiac or control antibodies. Human umbilical
vein endothelial cells were grown inside matrigel in the presence of
celiac patient-derived total IgA (CD IgA) or monoclonal antibodies
(CD Mab), or their relevant controls (non-CD IgA or non-CD
Mab) for ten days in a Cell-IQ system. During the assay pictures
were taken every five minutes.
(MPEG)
Video S2 Positron emission tomography (PET) and
positron emission tomography/computed tomography
(PET/CT) scanning 3D video from a mouse with
matrigel implants. PET and PET/CT scanning video of a
mouse with matrigel implants without any supplementation (basal)
or supplemented with celiac disease-specific transglutaminase 2-
targeted monoclonal autoantibodies (CD Mab) or its relevant
control (non-CD Mab). One mouse received three implants (basal,
CD Mab or non-CD Mab), each injected subcutaneously into
separate limbs as highlighted by circles in the video.
(MPEG)
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